Volume : III, Issue : IV, April - 2013

Designing and Development of Potent Drug Inhibitor to IL13RA2 in Asthma Disease

Rajath Pujari, Basavaraj Udapudi, Deepak Yaraguppi

Abstract :

Asthma is a chronic (long–term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you eathe), chest tightness, shortness of eath, and coughing. Asthma affects people of all ages, but it most often starts during childhood. IL–13 receptor (IL–13R) is a heterodimer composed of the IL–13Rα1 chain (IL–13Rα1) and the IL–4Rα chain (IL–4Rα), both IL–13 and IL–4 activate STAT6 and STAT3. IL–13Rα2 chain (IL–13Rα2) binds to IL–13 with high affinity and it does not contain the Box1 motif which is an important domain for intracellular signaling. IL13Rα2 was the target protein because it does not associate with signaling molecules and instead acts as a “decoy” receptor. The studies were performed on IL13Rα2 to inhibit the protein that expressed during the causes for asthma disease. The potential drug with IUPAC name “5–[2–(tert–butylamino)–1–hydroxyethyl]–2–(hydroxymethyl)” was designed successfully in inhibit the actions of IL13Rα2 protein.

Keywords :

Article: Download PDF   DOI : 10.36106/ijar  

Cite This Article:

Rajath Pujari, Basavaraj Udapudi, Deepak Yaraguppi Designing and Development of Potent Drug Inhibitor to IL13RA2 in Asthma Disease Indian Journal of Applied Research, Vol.III, Issue.IV April 2013

Number of Downloads : 1128

References :